CurrentRheuma
Get Weekly

Rheumatology journalCurrentRheuma coverage

The Lancet Rheumatology

What CurrentRheuma has captured from this journal. The coverage figures describe CurrentRheuma's coverage, not the journal's output. Figures as of 14 November 2026.

CurrentRheuma holds 184 Briefs from The Lancet Rheumatology, most often cohort studies and randomized controlled trials.

Recent
10 Briefs
past 90 days
Archive
184 Briefs
research published from January 2023 to today · 20 undated
Editorial
–
no Weekly issue published yet

Topics

Evidence types

Shares are of the 184 Briefs CurrentRheuma has covered from Lancet Rheumatol, by primary topic and study type; a Brief without a primary topic is in no topic row.

Publication activity

Latest from The Lancet Rheumatology

All coverage, newest first

  1. Lancet Rheumatol

    The IgG4ward! Foundation guidelines on the treatment of IgG4-related disease

    Guideline or statementAutoinflammatory & rare

  2. Lancet Rheumatol

    Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    Randomized controlled trialLupus & APS

  3. Lancet Rheumatol

    Effect of ethnicity on response to treatment escalation in patients with systemic lupus erythematosus from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a longitudinal cohort study

    Cohort studyLupus & APS

  4. Lancet Rheumatol

    Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study

    Cohort studySystemic sclerosis

  5. Lancet Rheumatol

    Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial

    Secondary analysisRA

  6. Lancet Rheumatol

    Predicting prevalence and severity of cytokine release syndrome after CAR T-cell therapy in patients with autoimmune disease: a retrospective cohort study

    Cohort studyAcross diseases

  7. Lancet Rheumatol

    Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial

    Randomized controlled trialFibromyalgia & pain

  8. Lancet Rheumatol

    Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study

    Cohort studyLupus & APS

  9. Lancet Rheumatol

    Minimal residual disease flow cytometry of peripheral blood B-cell subsets in patients with idiopathic inflammatory myopathies following rituximab therapy: a single-centre, retrospective cohort study

    Cohort studyMyositis

  10. Lancet Rheumatol

    ERN ReCONNET–SLICC–SLEuro consensus on the therapeutic management of rare systemic lupus erythematosus manifestations (part 2)

    Guideline or statementLupus & APS

  11. Lancet Rheumatol

    Defining age-related thresholds in hand, wrist, and foot ultrasound: an international, cross-sectional, observational study by the Outcome Measures in Rheumatology Ultrasound Working Group

    Cross-sectional studyOsteoarthritis

  12. Lancet Rheumatol

    Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials

    Meta-analysisRA

  13. Lancet Rheumatol

    Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study

    Cohort studySjögren's & overlap

  14. Lancet Rheumatol

    Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial

    Randomized controlled trialRA

  15. Lancet Rheumatol

    Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study

    Cohort studySpondyloarthritis & PsA

  16. Lancet Rheumatol

    Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY

    Cohort studyAcross diseases

  17. Lancet Rheumatol

    The role of health literacy in clinical, treatment, and work-related outcomes in people with inflammatory arthritis in England: a cross-sectional study

    Cross-sectional studyRA

  18. Lancet Rheumatol

    Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial

    Randomized controlled trialSjögren's & overlap

  19. Lancet Rheumatol

    Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial

    Randomized controlled trialLupus & APS

  20. Lancet Rheumatol

    Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study

    Cross-sectional studySpondyloarthritis & PsA

  21. Lancet Rheumatol

    Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study

    Randomized controlled trialRA

  22. Lancet Rheumatol

    Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study

    Cohort studyRA

  23. Lancet Rheumatol

    Associated lifestyle factors and comorbidities of difficult-to-treat rheumatoid arthritis: a systematic review and meta-analysis

    Meta-analysisRA

  24. Lancet Rheumatol

    Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study

    Meta-analysisSystemic sclerosis

  25. Lancet Rheumatol

    Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial

    Secondary analysisRA

  26. Lancet Rheumatol

    Development of patient-initiated follow-up resources for UK rheumatology departments: a co-design study with patient and clinician collaboration

    Research articleAcross diseases

  27. Lancet Rheumatol

    Time to pregnancy in women with rheumatoid arthritis who want to conceive treated according to a treat-to-target approach: a comparison of an observational cohort with a historical reference cohort

    Cohort studyRA

  28. Lancet Rheumatol

    Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study

    Cohort studyAutoinflammatory & rare

  29. Lancet Rheumatol

    A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial

    Randomized controlled trialGout & crystals

  30. Lancet Rheumatol

    Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab

    Randomized controlled trialPediatric

  31. Lancet Rheumatol

    Recombinant herpes zoster vaccine in patients with autoimmune rheumatic diseases in Brazil: a double-blind, randomised, placebo-controlled, phase 4, non-inferiority study

    Randomized controlled trialAcross diseases

  32. Lancet Rheumatol

    Worldwide trends in hyperuricaemia from 2000 to 2023: a systematic review and modelling analysis

    Meta-analysisGout & crystals

  33. Lancet Rheumatol

    Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL study

    Cohort studyLupus & APS

  34. Lancet Rheumatol

    Strengthening patient and public involvement in digital health innovation: reflective analysis of the development and real-world testing of the MyRA application

    Cohort studyRA

  35. Lancet Rheumatol

    Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

    Randomized controlled trialRA

  36. Lancet Rheumatol

    Transcutaneous auricular vagus nerve stimulation versus sham stimulation in patients with erosive hand osteoarthritis (ESTIVAL): a randomised, multicentre, double-blind, sham-controlled trial

    Randomized controlled trialOsteoarthritis

  37. Lancet Rheumatol

    Trends in mortality due to haemophagocytic lymphohistiocytosis across 29 European countries from 2011 to 2021: a retrospective, international, population-based study

    Cohort study

  38. Lancet Rheumatol

    Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies

    Randomized controlled trialSpondyloarthritis & PsA

  39. Lancet Rheumatol

    Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

    Cross-sectional studyLupus & APS

  40. Lancet Rheumatol

    Clinical phenotypes, classification, and long-term outcomes of childhood-onset Sjögren's disease into adulthood: a single-centre cohort study

    Cohort studyPediatric

All 184 Briefs in ExploreShowing the 40 most recently published